Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2745-2754

  Schwartzberg, Lee S ^a   Tauer, Kurt W ^a   Hermann, Robert C ^c   Makari Judson, Grace ^e   Isaacs, Claudine ^f   Beck, J Thaddeus ^g   Kaklamani, Virginia ^h   Stepanski, Edward J ^b   Rugo, Hope S ^j   Wang, Wei ^k   Bell McGuinn, Katherine ⁿ   Kirshner, Jeffrey J ^o   Eisenberg, Peter ^l   Emanuelson, Richard ^q   Keaton, Mark ^d   Levine, Ellis ^p   Medgyesy, Diana C ^r   Qamar, Rubina ^s   Starr, Alexander ⁱ   Ro, Sunhee Kwon ^m   Lokker, Nathalie A ^m   Hudis, Clifford A ⁿ   more..

^a West Clinic   (United States)

^b ACORN Research LLC   (United States)

^c Northwest Georgia Oncology Centers   (United States)

^d Augusta Oncology Associates   (United States)

^e BAYSTATE HEALTH   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g Highlands Oncology Group   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ Monroe Medical Asociates   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^l Marin Cancer Institute   (United States)

^m ONYX PHARMACEUTICALS   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o Hematology Oncology Asociates of Central   (United States)

^p ROSWELL PARK CANCER INSTITUTE   (United States)

^q P   (United States)

^r Front Range Veterinary Clinic   (United States)

^s Advanced Healthcare   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PLACEBO; SORAFENIB; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; NICOTINAMIDE;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SKIN DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECEPTOR, ERBB-2; SKIN DISEASES; STOMATITIS; TREATMENT OUTCOME;

EID: 84878059586     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3177     Document Type: Article

References (35)

1. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007;4:536-50.
2. Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20:616-24.
3. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30:117-24.
4. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26: 1810-6.
5. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28: 3239-47.
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
7. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-93.
8. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
9. Fojo T, Wilkerson J. Bevacizumab and breast cancer: the E2100 outlier. Lancet Oncol 2010;11:1117-9.
10. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;13 Suppl 2:19-21.
11. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32.
12. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
13. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31.
14. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8.
15. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, et al. A feasibility study of bevacizumab plus dose-dense doxorubicincyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 2011;17: 3398-407.
16. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010;116:5383-90.
17. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
18. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
19. Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30:1484-91.
20. Gradishar W, Kaklamani V, Prasad Sahoo T, Lokanatha D, Raina V, Bondarde S, et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combinationwith paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013;49:312-22.
21. Mariani G, Burdaeva O, Roman L, Staroslawska E, Udovitsa D, Driol P, et al. A double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer: FM-B07-01 Trial. Eur J Cancer 2011;47: Abstract 17LBA.
22. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Invasive breast cancer. J Natl Compr Canc Netw 2011;9: 136-222.
23. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009;CD003372.
24. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51.
25. Awada A, Gil T, Whenham N, Vanhamme J, Mancini I, Besse T, et al. Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors. Ann Oncol 2007 (suppl; abstr 402);18:iv39.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
27. Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 2004;190: 666-74.
28. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011;29: 264-71.
29. Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J, et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 2001;66: 83-7.
30. Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V, et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 2000;9:338-42.
31. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002;62:2-8.
32. Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999;10:625-31.
33. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29:83-8.
34. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ. Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). J Clin Oncol 2011;29 suppl 15, abstr TPS124.
35. Alsina M, Ruiz-Echarri M, Capdevila J, Munoz E, Tabernero J. Biomarkers for therapies directed at angiogenesis. Curr Colorectal Cancer Rep 2010;6:133-43.